Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study

Barnadas, A.; Mendiola, C.; Casado, Antonio; A, Villar; Jimeno, J.; Clerigué, Montserrat; Rosell, Rafael; Díaz-Rubio, Eduardo; Cortés, Javier; Paredes, Marisa García de

doi:10.1016/s0959-8049(96)00372-3

Cited by 8 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…113 Thus, Rb-deficient tumor cells are more sensitive than isogenic, Rb-proficient cells to chemotherapy but more resistant to hormonal therapy. Currently, no specific therapy for Basal-like or Claudin-low BC is available, and these patients are treated with combinations of cytotoxic drugs, such as Docetaxel-Carboplatin, 114 IdarubicinPrednimustine 115 and CyclophosphamideMethotrexate-fluorouracil 5FU (CMF). 116 Clearly, Basal-like and Claudin-low tumors are distinct subtypes and should be treated with specific regimens.…”

Section: Targeting the Rb-p53-emt Circuit In Tnbcmentioning

confidence: 99%

RB1 and p53 at the crossroad of EMT and triple-negative breast cancer

Jiang¹,

Jones²,

Liu³

et al. 2011

Cell Cycle

View full text Add to dashboard Cite

Section: Targeting the Rb-p53-emt Circuit In Tnbcmentioning

confidence: 99%

RB1 and p53 at the crossroad of EMT and triple-negative breast cancer

Jiang¹,

Jones²,

Liu³

et al. 2011

Cell Cycle

View full text Add to dashboard Cite

“…Other combinations attracting interest include capecitabine plus oral idarubicin [135], capecitabine plus oral cyclophosphamide [136], capecitabine/ idarubicin/cyclophosphamide triple combination [124], and capecitabine plus tipifarnib [137]. Studies of metronomic therapy using an all-oral combination of cyclophosphamide and methotrexate suggest that this is an effective and minimally toxic approach [128][129][130]. In a large trial in patients with treated or untreated advanced breast cancer, low-dose oral cyclophosphamide and methotrexate produced responses in 21% of patients and median overall survival of 18.2 months [128].…”

Section: All-oral Combinationsmentioning

confidence: 99%

Effective oral chemotherapy for breast cancer: pillars of strength

2008

View full text Add to dashboard Cite

Traditionally, anticancer therapy has been dominated by intravenous drug therapy. However, oral agents provide an attractive approach to chemotherapy and use of oral treatments is increasing. We discuss the benefits and challenges of oral chemotherapy from the perspectives of patients, healthcare providers and healthcare funders. Important issues include patient preference, efficacy, compliance, bioavailability, reimbursement, use in special patient populations, financial and staff time savings and flexibility of dosing. We review data for traditional oral agents (e.g. cyclophosphamide, methotrexate), newer oral chemotherapies (e.g. capecitabine), oral formulations of traditionally intravenous agents (e.g. vinorelbine, idarubicin) and new biologic agents under evaluation in breast cancer (e.g. tyrosine kinase inhibitors). Lastly, we review studies of all-oral combination regimens. The wealth of data available and the increasing use of oral agents in breast cancer suggest that many of the concerns and perceptions about oral therapy, including efficacy and bioavailability, have been overcome, and that oral therapy will play a major role in breast cancer management in the future in both the metastatic and adjuvant settings. Key words: breast cancer, capecitabine, oral chemotherapy, vinorelbine introduction Cancer treatment has traditionally been dominated by intravenous drug therapy [1]. There has, however, been a steady increase in the number of oral anticancer agents available during recent years, offering obvious benefits in terms of convenience and ease of administration, as well as addressing patients' preference for oral therapy [2][3][4][5]. It is estimated that one-quarter of all anticancer agents under development are oral agents [6]. Several agents that are already approved in a range of tumour types (e.g. capecitabine, erlotinib, gefitinib, imatinib, lapatinib, lenalidomide, thalidomide, sunitinib, sorafenib) and many others in development (e.g. vatalanib, satraplatin) are or will be available only as oral formulations. Novel approaches to drug delivery, such as the development of hydrophilic polymer carriers to deliver drugs to the gut [7], are likely to further increase the number of oral drugs available.This review investigates the impact of the expanding range of oral agents on cancer treatment, focusing on issues that have previously prevented the use of oral agents in patients with cancer and the opportunities that oral therapy offers. Oral agents that are already available, or that are under clinical evaluation for the treatment of breast cancer, are profiled to illustrate the potential of oral chemotherapy in this patient group.defining the ideal oral agent the patient's perspective Several surveys have shown that most patients prefer oral to intravenous therapy [3,4,8]. Nevertheless, a minority of patients prefer intravenous therapy because they believe that oral therapy is less effective than intravenous treatment [5,8,9]. In a survey of 59 patients starting oral chemotherapy for advanced breas...

show abstract

A Pharmacokinetic Study of Idarubicin in Japanese Patients With Malignant Lymphoma: Relationship With Leukocytopenia and Neutropenia

et al. 2001

View full text Add to dashboard Cite

To clarify the pharmacokinetic properties of idarubicin (IDA) in Japanese patients and to clarify the relationship between the pharmacokinetic parameters of IDA or idarubicinol (IDAol), an active metabolite of IDA, and leukocytopenia or neutropenia, we examined the pharmacokinetics of IDA in patients with malignant lymphoma. Nine of 21 patients registered in an early phase II study of IDA were enrolled in the pharmacokinetic study. IDA (12 or 15 mg/m2) was administered by intravenous infusion for 5 minutes. The elimination half lives (t 1/2) of IDA were 11.0 hours and 12.5 hours after administration of 12 and 15 mg/m2 IDA, respectively. IDAol appeared rapidly both in plasma and in blood cells, and its concentrations exceeded those of IDA within 4 hours. IDAol had a very long t 1/2 (69.2 hours and 70.0 hours for 12 and 15 mg/m2, respectively). The areas under the concentration curves of IDAol in plasma were 3.4 and 5.8 times higher than those of IDA after administration of 12 and 15 mg/m2 IDA, respectively. The t 1/2 of IDAol in plasma correlated significantly with the nadir of neutrophils, and the steady-state volume of distribution of IDA in plasma and in blood cells correlated significantly with the nadirs of white blood cells and neutrophils. These results suggest that both IDA and IDAol play an important role in leukocytopenia or neutropenia. No substantial differences between Japanese and Caucasian people in the pharmacokinetics of IDA were apparent.

show abstract

Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study

Cited by 8 publications

References 12 publications

RB1 and p53 at the crossroad of EMT and triple-negative breast cancer

RB1 and p53 at the crossroad of EMT and triple-negative breast cancer

Effective oral chemotherapy for breast cancer: pillars of strength

A Pharmacokinetic Study of Idarubicin in Japanese Patients With Malignant Lymphoma: Relationship With Leukocytopenia and Neutropenia

Contact Info

Product

Resources

About